Literature DB >> 17531717

Photodynamic therapy for posterior capsule neovascularization.

Ali Ayata1, Melih Unal, Dilaver Erşanli, Oğuz Gülecek, Murat Sönmez.   

Abstract

We report a 71-year-old man with posterior capsule opacification with severe neovascularization who was treated with photodynamic therapy and neodymium:YAG capsulotomy. Treatment was performed using a diode laser at 692 nm, a light dose of 50 J/cm(2), and 6 mg/m(2) body surface area verteporfin. The initial visual acuity was hand motions; 6 months after therapy, the visual acuity was stable at 20/200. In 9 months of follow-up, there was no recurrence of neovascularization and the pupil area remained clear; no retreatment was needed. Photodynamic therapy provided safe and effective occlusion of neovascular vessels in the posterior capsule area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531717     DOI: 10.1016/j.jcrs.2007.02.025

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  Intravitreal Bevacizumab for posterior capsule neovascularization.

Authors:  Mansour Al-Mohaimeed
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

2.  Posterior lens capsule neovascularization treated with anti-VEGF complicated by phacogenic uveitis.

Authors:  Felicia Tai; Efrem D Mandelcorn; Sohel Somani
Journal:  Am J Ophthalmol Case Rep       Date:  2020-10-03

3.  Intravitreal bevacizumab for posterior capsule neovascularization.

Authors:  Mansour Al-Mohaimeed; Saeed Al-Gehedan; Hassan Al Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-04-02

4.  Posterior capsule opacification and neovascularization treated with intravitreal bevacizumab and Nd:YAG capsulotomy.

Authors:  Grimelda Yuriana Sánchez-Castro; Alejandra Hitos-Fájer; Erick Mendoza-Schuster; Raul Velez-Montoya; Cecilio Francisco Velasco-Barona
Journal:  Clin Ophthalmol       Date:  2008-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.